ES2542328T3 - Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma - Google Patents

Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma Download PDF

Info

Publication number
ES2542328T3
ES2542328T3 ES03796633.0T ES03796633T ES2542328T3 ES 2542328 T3 ES2542328 T3 ES 2542328T3 ES 03796633 T ES03796633 T ES 03796633T ES 2542328 T3 ES2542328 T3 ES 2542328T3
Authority
ES
Spain
Prior art keywords
markers
protein
expression
marker
prediction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03796633.0T
Other languages
English (en)
Spanish (es)
Inventor
George Mulligan
Barbara M. Bryant
Michael P. Morrissey
Andrew Bolt
Andrew I. Damokosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32507743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2542328(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2542328T3 publication Critical patent/ES2542328T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
ES03796633.0T 2002-12-06 2003-12-04 Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma Expired - Lifetime ES2542328T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43151402P 2002-12-06 2002-12-06
US431514P 2002-12-06
PCT/US2003/038539 WO2004053066A2 (en) 2002-12-06 2003-12-04 Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy

Publications (1)

Publication Number Publication Date
ES2542328T3 true ES2542328T3 (es) 2015-08-04

Family

ID=32507743

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03796633.0T Expired - Lifetime ES2542328T3 (es) 2002-12-06 2003-12-04 Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma

Country Status (8)

Country Link
US (3) US20040156854A1 (enExample)
EP (1) EP1581629B1 (enExample)
JP (2) JP5717937B2 (enExample)
AU (1) AU2003298873B2 (enExample)
CA (1) CA2508348C (enExample)
ES (1) ES2542328T3 (enExample)
MX (1) MXPA05005923A (enExample)
WO (1) WO2004053066A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20090215024A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Biomarkers upregulated in prostate cancer
US20090226915A1 (en) * 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US20090215058A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
AU2003300899A1 (en) * 2002-12-12 2004-06-30 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
JP2007529426A (ja) * 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
CA3002661C (en) 2004-05-21 2022-03-15 The Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
EP1828917A4 (en) * 2004-11-12 2012-04-25 Health Discovery Corp BIOMARKERS FOR DETECTING, PREDICTING AND MONITORING PROSTATE DISEASE
WO2006101535A1 (en) * 2005-03-23 2006-09-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of proteasome function to potentiate the proapoptotic and antitumor activity of cytokines
WO2006112400A1 (ja) * 2005-04-18 2006-10-26 National University Corporation Hamamatsu University School Of Medicine 癌の転移性及び浸潤能の検査方法
JP5904569B2 (ja) * 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
EP1912664A2 (en) * 2005-07-06 2008-04-23 Biodevelops Pharma Entwicklung GmbH Use of a compound for enhancing the expression of membrane proteins on the cell surface
WO2007022041A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Mutations and polymorphisms of hdac3
US20070071762A1 (en) * 2005-09-21 2007-03-29 Ccc Diagnostics, Llc Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
CA2632188A1 (en) * 2005-11-10 2007-05-24 Rosetta Inpharmatics Llc Discover biological features using composite images
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
CN100372568C (zh) * 2005-12-09 2008-03-05 中国科学院广州生物医药与健康研究院 化合物mg-132在制备治疗白血病药物中的应用
US7875274B2 (en) * 2005-12-16 2011-01-25 The Board Of Trustees Of The Leland Stanford Junior University Protein modulators of resistance to alkylating agents
US20070292869A1 (en) * 2006-03-02 2007-12-20 Ppd Biomarker Discovery Sciences, Llc Compositions and Methods for Analyzing Renal Cancer
CA2646065C (en) * 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
EP2021502A4 (en) * 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
EP2484688B1 (en) 2006-06-19 2016-06-08 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
EP2046973A4 (en) * 2006-08-10 2010-04-07 Millennium Pharm Inc METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY
US20100113392A1 (en) * 2006-11-03 2010-05-06 Badros Ashraf Z Methods of using saha and bortezomib for treating multiple myeloma
JP5413818B2 (ja) * 2007-03-29 2014-02-12 国立大学法人佐賀大学 蛍光多重染色による蛋白定量法
CA2683643C (en) * 2007-04-10 2015-11-24 Martin G. Pomper Imaging and therapy of virus-associated tumors
US20080317768A1 (en) * 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
CN110372795A (zh) 2007-08-02 2019-10-25 吉利德生物制剂公司 Lox和loxl2抑制剂及其应用
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
EP2227693B1 (en) 2007-11-30 2015-08-19 Clarient Diagnostic Services, Inc. Tle3 as a marker for chemotherapy
WO2009076551A2 (en) * 2007-12-12 2009-06-18 The Regents Of The University Of California Systems and methods for predicting response of biological samples
WO2009148528A2 (en) * 2008-05-30 2009-12-10 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
US8321144B2 (en) * 2008-10-23 2012-11-27 Microsoft Corporation Non-contiguous regions processing
US20110263442A1 (en) * 2008-10-29 2011-10-27 Jan Akervall Method of using biomarkers
US20120015906A1 (en) * 2009-01-02 2012-01-19 Shaughnessy Jr John D Uses of bortezomib in predicting survival in multiple myeloma patients
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
BR112012008080A2 (pt) * 2009-08-21 2017-07-04 Gilead Biologics Inc ensaios de rastreamento in vivo.
RU2012110585A (ru) * 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Каталичические домены лизилоксидазы и loxl2
AU2010284001A1 (en) * 2009-08-21 2012-03-22 Gilead Biologics, Inc. Therapeutic methods and compositions
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
CA2771774A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. In vitro screening assays
US8853147B2 (en) * 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
WO2011094806A1 (en) * 2010-02-03 2011-08-11 Monash University Diagnostic and prognostic assay for breast cancer
RU2015108348A (ru) 2010-02-04 2015-07-20 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
JP5740880B2 (ja) 2010-09-15 2015-07-01 株式会社リコー 画像形成装置、及びプログラム
SI2742356T1 (sl) * 2011-08-11 2016-06-30 Janssen Pharmaceutica N.V. Prediktorji pri zdravljenju raka
US20150184246A1 (en) * 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
WO2014078571A1 (en) * 2012-11-14 2014-05-22 The Board Of Trustees Of The University Of Arkansas Methods of detecting 14q32 translocations
EP3305916B1 (en) 2013-05-20 2019-06-26 BioVentures, LLC Gep5 model for multiple myeloma
ES2923942T3 (es) 2013-11-06 2022-10-03 Us Health Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
US20170166974A1 (en) * 2014-05-20 2017-06-15 Erasmus University Medical Center Rotterdam Method for the treatment of multiple myeloma
US10607152B2 (en) * 2015-05-26 2020-03-31 Textio, Inc. Using machine learning to predict outcomes for documents
US20170159130A1 (en) * 2015-12-03 2017-06-08 Amit Kumar Mitra Transcriptional classification and prediction of drug response (t-cap dr)
USRE50076E1 (en) 2015-12-30 2024-08-13 Hyundai Heavy Industries Co., Ltd. Liquefied gas carrier
WO2017184861A1 (en) 2016-04-20 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Evaluation of mantle cell lymphoma and methods related thereto
CN106928370B (zh) * 2016-09-26 2021-02-02 华东师范大学 一种REGγ-20S蛋白酶体抑制剂的筛选系统及其应用
US11804298B2 (en) 2017-07-17 2023-10-31 Joon Kim Cancer diagnostic apparatus and cancer diagnostic system using the same
KR102007664B1 (ko) * 2017-07-17 2019-08-07 김준 암 진단기 및 이를 이용한 암 진단시스템
US11899022B2 (en) 2017-08-23 2024-02-13 The General Hospital Corporation Multiplexed proteomics and predictive drug candidate assessment
EP3502279A1 (en) * 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
US12433488B2 (en) * 2018-01-17 2025-10-07 14336186 Canada Corp. (Exclaro) System and methods for real time raman spectroscopy for cancer detection
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
US20230340604A1 (en) * 2022-04-20 2023-10-26 Morehouse School Of Medicine Methods of treatment and diagnosis of multiple myeloma progression

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2077665A1 (en) 1990-03-05 1991-09-06 Robert Siman Chymotrypsin-like proteases and their inhibitors
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
WO2001002567A1 (en) * 1999-07-02 2001-01-11 Millennium Pharmaceuticals, Inc. 16405 receptor, a g-protein coupled receptor
WO2001064837A2 (en) * 2000-02-29 2001-09-07 The General Hospital Corporation β NETRIN AND USES THEREOF
US20040006205A1 (en) * 2001-04-03 2004-01-08 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030185815A1 (en) * 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CA2446806A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
JP5904569B2 (ja) * 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
JP5717937B2 (ja) 2015-05-13
EP1581629B1 (en) 2015-04-01
HK1086027A1 (en) 2006-09-08
WO2004053066A3 (en) 2006-09-08
JP2010207230A (ja) 2010-09-24
EP1581629A4 (en) 2007-05-16
CA2508348A1 (en) 2004-06-24
US20170023577A1 (en) 2017-01-26
CA2508348C (en) 2016-07-12
AU2003298873A1 (en) 2004-06-30
AU2003298873B2 (en) 2011-09-01
JP5896593B2 (ja) 2016-03-30
US20090181393A1 (en) 2009-07-16
MXPA05005923A (es) 2005-09-21
JP2006517093A (ja) 2006-07-20
EP1581629A2 (en) 2005-10-05
US20040156854A1 (en) 2004-08-12
WO2004053066A2 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
ES2542328T3 (es) Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
US9500656B2 (en) Methods for the identification, assessment, and treatment of patients with cancer therapy
ES2624863T3 (es) Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
ES2656487T3 (es) Evaluación de la respuesta a la terapia de neoplasmas neuroendocrinos gastroenteropancreáticas (GEP-NEN)
CN107034295B (zh) 用于癌症早期诊断和危险度评价的dna甲基化指标及其应用
CN103733065A (zh) 用于癌症的分子诊断试验
US20230160017A1 (en) Prediction of radiotherapy response for prostate cancer subject based on immune defense response genes
CN112501290B (zh) 与乳腺癌预后相关的标志分子以及检测试剂盒
Chen et al. Development and validation of nomogram with tumor microenvironment-related genes and clinical factors for predicting overall survival of endometrial cancer
US20240182984A1 (en) Methods for assessing proliferation and anti-folate therapeutic response
US20150011411A1 (en) Biomarkers of cancer
Liu et al. Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation
HK1086027B (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
Chen et al. Upregulation of B3GNT3 Correlates With Poor Prognosis and Decreased Immune Cell Infiltration In Pancreatic Adenocarcinoma
WO2022103947A2 (en) Lactotransferrin and mif promoter polymorhpism detection for cancer detection and treatment
WO2019215394A1 (en) Arpp19 as biomarker for haematological cancers
HK1238302A (en) Dna methylation biomarker for early detection and risk assessment of cancer